Here’s what Wall Street is saying about obesity drug Wegovy following Novo Nordisk’s key study
[ad_1] Analysts are largely optimistic about a new class of anti-obesity medications following a landmark study released over the weekend. Novo Nordisk ‘s Select study of about 17,500 people found the use of its Wegovy decreased the risk of serious cardiovascular complications such as heart attacks. The study, which was shared at the American Heart…
